World's first gene therapy operation conducted for macular d
Oxford researchers have carried out the world’s first gene therapy operation to tackle the root cause of age-related macular degeneration (AMD).

The procedure was a part of a clinical trial performed at the John Radcliffe Hospital by Prof Robert MacLaren, Professor of Ophthalmology at the University of Oxford, with the support of the National Institute for Health Research (NIHR), Oxford Biomedical Research Centre.

The operation is the first in the phase 1/2 FOCUS trial, an open-label, dose escalation, multicenter study accessing the biological activity of the treatment. The procedure has been developed by Gyroscope Therapeutics.

The operation involved detaching the retina and injecting a solution containing a virus - composed of modified DNA sequence.

The virus infects specific cells, called the Retinal pigment epithelium (RPE) on injection and corrects the genetic defect that causes AMD. The process needs to be performed once, as the effects are thought to be long-lasting.

The first person to undergo the procedure was Mrs. Janet Osborne from Oxford whose motivation for being part of the trial was - 'I wasn't thinking of me. I was thinking of other people.'

Read the complete story here:
Dr. K●●●n B●●●●●●●e and 2 other likes this
Dr. P●●●●●●a N K●●●●●n
Dr. P●●●●●●a N K●●●●●n Ophthalmology
Can save eye sight of many patients.
Feb 21, 2019Like